Not Tagged
Not Tagged
['rectal', 'prospect trial']
late breaking at #asco23: in the prospect trial comparing preoperative chemoradiotherapy and folfox in patients with rectal cancer undergoing sphincter-sparing surgery, 5-year disease-free survival was 80.8% with folfox and 78.6% with chemoradiotherapy. 
The New England Journal of Medicine (https://t.co/YGfDrRsIhE) is the world’s leading medical journal and website.